>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
血清KL-6与慢性阻塞性肺疾病关系
作者:覃锦玉1  林勇2 
单位:1. 东南大学医学院,江苏 南京 210009;
2. 东南大学附属中大医院 呼吸科,江苏 南京 210009
关键词:KL-6 慢性阻塞性肺疾病 血清标志物 肺损伤 氧化应激 综述 
分类号:R563
出版年·卷·期(页码):2012·31·第四期(500-503)
摘要:

慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)为一致死及致残性高的疾病,尤其是在急性加重期过后,患者的临床症状虽有所缓解,但其肺功能仍在继续恶化。临床迫切需要寻找特异性和敏感性较高的血清标志物作为COPD的早期诊断、治疗及预后的评估指标。血清KL-6是一种衡量肺泡组织损伤的特异性生物标志物,其是否能作为评价COPD患者的严重程度和预后的一种生化指标有待进一步研究。作者就COPD的炎症机制、肺损伤、氧化应激及与血清KL-6相关性作一简要综述。

参考文献:

[1] CRUL T,SPRUIT M A,GAYAN-RAMIREZ G,et al.Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients[J].Eur J Clin Inv,2007,11(37):897-904.
[2] GOLD Executive Committee.Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease(Revised 2011).www.goldcopd.com.
[3] TOBIN M J.Chronic obstructive pulmonary disease,pollution,pulmonary vascular disease,transplantation,pleural disease,and lung cancer in AJRCCM 2002[J].Am J Respir Crit Care Med,2003,167(3):356-370.
[4] LEUCHTE H H,BAUMGARTNER B A,NOUNOU M E,et al.Brain natriurefie peptide is a prognostic parameter in chronic lung disease[J].Am J Respir Crit Care Med,2006,173(7):744-750.
[5] YOUNG T,PEPPARD P E,GOTTLIEB D J,et al.Epidemiologyo for obstructive sleep apnea:a population health perspective[J].Am J Respir Crit Care Med,2002,165(9):1217-1239.
[6] VIBHUTI A,ARIF E,DEEPAK D,et al.Correlation of oxidative status with BMI and lung function in COPD[J].Clin Biochem,2007,40(13-14):958-963.
[7] LANG J D,MCARDLE P J,ORCIUY P J,et al.Oxidant-antioxidant balance in acute lung injury[J].Chest,2002,122(6 Suppl):314S-320S.
[8] MacNEE W,RAHMAN I.Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease?[J].Trends Mol Med,2001,7(2):55-62.
[9] FARKHUTDINOV U R,ABDRAKHMANOVA L M,FARKHUTDINOV R R,et al.Effects of halotherapy on free radical oxidation in patients with chronic bronchitis[J].Klin Med,2000,78:37-40.
[10] RAHMAN I,SKWARSKA E,MacNEE W,et al.Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease[J].Thorax,1997,52:565-568.
[11] KOHNO N,AKIYAMA M,KYOIZUMI S,et al.Detection of soluble tumor-associated antigen in sera and effusions using novel monoclonal antibodies,KL-3 and KL-6,a gainst lung adenocarinomal[J].Jpn J Clin Oncol,1998,18(3):203-216.
[12] SATO H,CALLISTER M E,MUMBY S,et al.KL-6 Levels are elevated in plasma form patients with acute respiratory distress syndrome[J].Eur Respir J,2004,23(1):142-145.
[13] OGAWA Y,ISHIKAWA T,IKEDA K,et al.Evaluation of serum KL-6,a mucin-like glycoprotein,as a tumor marker for breast cancer[J].Clin Cancer Res,2000,6:4069-4072.
[14] KOHNO N,INOUE Y,HAMADA H,et al.Difference insero-diagnostic values among KL-6-associated mucins classified as cluster 9[J].Int J Cancer Suppl,1994,8:81-83.
[15] HIRASAWA Y,KOHNO N,YOKOYAMA A,et al.KL-6,a human MUC1 mucin,is chemotactic for human fibroblasts[J].Am J Respir Cell Mol Biol,1997,17:501-507.
[16] OHNISHI H,YOKOYAMA A,KONDO K,et al.Comparative study of KL-6,surfactant protein-A,surfactant protein-D,and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases[J].Am J Respir Crit Care Med,2002,165:378-381.
[17] INOUE Y,NISHIMURA K,SHIODE M,et al.Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis[J].Tuber Lung Dis,1995 ,76(3):230-233.
[18] SATO H,CALLISTER M E,MUMBY S,et al.KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome[J].Eur Respir J,2004,23:142-145.
[19] LIN F C,CHEN Y C,CHANG S C.Clinical importance of bronchoalveolar lavage fluid and blood cytokines,surfactant protein D,and derbs von lungren 6 antigen in idiopathic pulmonary alveolar proteinosis[J].Mayo Clin Proc,2008,83(12):1344-1349.
[20] GAN W Q,MAN S F,SENTHILSELVAN A,et al.Association between chronic obstructive pulmonary disease and systemic inflammation:a stematic review and a meta-analysis[J].Thorax,2004,59(7):574-580.
[21] MAN S F,CONNETT J E,ANTHONISEN N R,et al.C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease[J].Thorax,2006,61:849-853.
[22] DAHL M,VESTBO J,LANGE P,et al.C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2007,175:250-255.
[23] De TORRES J P,CORDOBA-IANUS E,LBPEZ-AGUILAR C,et al.C-reactive protein levels and clinically important predictive outcomes in stable COPD patients[J].Eur Respir J,2006,27:902-907.
[24] ARONSON D,ROTERMAN I,YIGLA M,et al.Inverse association between pulmonary function and C-reactive protein in apparently ealthy subjects[J].Am J Respir Crit Care Med,2006,174:626-632.
[25] SIN D D,MAN S F.Biomarkers in COPD:are we there yet?[J].Chest,2008,133:1336-1343.
[26] MacNEE W.Oxidative stress and lung inflammation in airways disease[J].Eur J pharmacol,2001,429:195-207.
[27] 陶玉坚,林勇,孙思庆.COPD大鼠呼吸道损伤的动态改变[J].东南大学学报:医学版,2003,22(6):384-387.
[28] ISHIKAWA N,HATTORI N,TANAKA S,et al.Levels of surfactant proteins A and D and KL-6 are elevated in the induced sputum of chronic obstructive pulmonary disease patients:a sequential sputum analysis[J].Respiration,2011,82(1):10-18.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 360652 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364